Comparative study of the effect of rivaroxaban and fondaparinux on monocyte’s coagulant activity and cytokine release by unknown
Experimental 
Hematology & Oncology
Laurent et al. Experimental Hematology & Oncology 2014, 3:30
http://www.ehoonline.org/content/3/1/30RESEARCH Open AccessComparative study of the effect of rivaroxaban
and fondaparinux on monocyte’s coagulant
activity and cytokine release
Marc Laurent1†, Ulrich Joimel1†, Rémi Varin1,2, Lionel Cazin1, Caroline Gest1, Veronique Le-Cam-Duchez1, Jian Jin3,4,
Jielin Liu3,5, Jean-Pierre Vannier1, He Lu3*, Jeannette Soria2, Hong Li1* and Claudine Soria1Abstract
Objectives: Tissue factor (TF) exposed on activated monocytes and macrophages is involved in thrombosis
through activation of factor X and cytokine release, responsible for inflammation and thrombosis. We investigated
the effect of two anti-factor Xa drugs: rivaroxaban, a direct anti-Xa inhibitor, and fondaparinux, an antithrombin
dependent anti-Xa inhibitor, on monocyte/macrophage procoagulant activity and cytokine release.
Methods: Rivaroxaban and fondaparinux were tested at pharmacological concentrations on LPS-activated monocytes
and on THP-1 cells, a human monocytic cell line, to assess 1) TF expression by flow cytometry 2) prothrombinase
activity by its coagulant activity and 3) cytokine release in cell supernatants by antibody based cytokine array and ELISA
for IL-8 and TNFα.
Results and conclusion: Rivaroxaban and fondaparinux did not modify TF expression level on activated cells. In
contrast procoagulant activity associated to monocytes and macrophages was dose dependently inhibited by
rivaroxaban, but not significantly by fondaparinux. These results could explain why patients undergoing major
orthopedic surgery with rivaroxaban prophylaxis were able to achieve significant reductions in venous
thromboembolism, compared with drugs commonly used, i.e. fondaparinux and low molecular weight heparin. In
addition, rivaroxaban and fondaparinux suppressed some chemokine secretion produced by activated macrophages.
This may also contribute to their antithrombotic effect in clinic.
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Newer antithrombotic drugs have been developed to im-
prove efficacy and safety for prevention and treatment of
venous and arterial thrombosis. Drug candidates are de-
signed to achieve a direct specific inhibition of coagulation
factors that are presumed to play an important role in
thrombogenesis. Among them, there are new orally active
antithrombotic agents targeting thrombin or factor Xa
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unless otherwise stated.Fondaparinux (Arixtra®) is a synthetic penta saccharide
that selectively binds to antithrombin III, potentiating
factor Xa neutralization thus inhibiting thrombin forma-
tion [2,3]. Rivaroxaban (Xarelto®) is a direct factor Xa
inhibitor which binds directly to the Xa active site,
blocking its activity [4]. Rivaroxaban is 100,000-fold
more selective for FXa than for other biological prote-
ases such as thrombin, plasmin, factor VIIa or factor
IXa. Both, fondaparinux and rivaroxaban inhibit throm-
bin generation in plasma when the coagulation cascade
is triggered by tissue factor (TF).
Activated coagulation factor X (FXa) is a major target
for designing anticoagulant drugs: it is located at the
convergence of the intrinsic and extrinsic coagulation
cascade, and activation of one molecule of factor X re-
sults in the generation of 1000 molecules of thrombinl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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surface results in prothrombinase complex formation, a
potent activator of prothrombin. This complex enhances
factor Xa catalytic efficacy by several orders of magnitude
in the rate of factor II activation into thrombin [7].
It is well established that in thrombosis, FXa gener-
ation results from an activation of coagulation cascade
initiated by TF expressed on activated endothelial cells
and activated monocytes/macrophages [8], while under
physiological conditions, endothelial cells and monocytes
/macrophages do not express TF and TF activity is coun-
terbalanced by TFPIs [9]. Endothelial cells secrete TFPIα
and express TFPIβ on the cell surface and TFPIs was
found bound to the surfaces of monocytes [10]. TFPIα
and TFPIβ inhibit both TF-factor VIIa-dependent factor
Xa (FXa) generation and free FXa. TFPIα inhibits pro-
thrombinases in the presence of Protein S and factor Va
[9,10]. In some pathological conditions, TF is over-
expressed by a variety of cells, including monocytes and
tumor cells, and the correct balance between TF and
TFPI is disrupted [9,11,12]. Monocytes and macro-
phages are the major cell type developing pro-coagulant
activity through TF expression induced by inflammatory
stimuli [13-17]. Monocyte thrombogenic activity could
contribute to thrombotic risk in surgery [18] and cancer
[19,20]. In fact, tumor associated macrophages express
a significantly higher level of TF than control cells [21].
Clinical studies have confirmed the major contribution
of TF expressed on activated monocytes in thrombosis
[22-24]. After plaque injury, as observed in angioplasty,
exposure of cellular and extracellular TF to circulating
blood play a pivotal role in mediating fibrin-rich thrombus
formation leading to acute coronary syndromes [25]. TF
expressed on monocytes/macrophages is up-regulated by
inflammatory cytokines and oxidized lipids from the plaque
[26]. Moreover, activated macrophages also acquire other
functional properties, including cytokine production that
may significantly participate in autocrine and paracrine
signaling among leukocytes and vascular endothelial cells
[27,28].
In addition to the extrinsic activation mediated by tissue
factor-factor VIIa, after inflammatory stimuli, monocytes
can initiate coagulation in an alternative procoagulant re-
sponse due to the binding of the zymogen factor X to the
integrin Mac-1 (CD11b/CD18) triggering monocyte de-
granulation and cathepsin G activation of factor X, which
catalyzes the cleavage of FX at a novel Leu177- Leu178
peptide bond to form an active protease [21,28-31]. The
newly generated factor Xa remains associated with the
monocyte membrane, and promotes procoagulant activity
and thrombin formation [9,21,28-31].
Finally, several lines of evidence suggest that both FXa
and thrombin, by binding to protease-activated receptors
(PAR) expressed on monocytes also elicit a cellularresponse inducing inflammatory cytokine release [32].
PAR-1 expressed by monocytes is cleaved by thrombin
and triggered thrombin-dependent inflammation [33].
PAR-2, expressed on monocytes and macrophages is
cleaved by FXa [34], contributing to a chronic inflamma-
tory state [28,29].
Since FXa acts as the key molecule in coagulation ampli-
fication (one molecule of factor Xa generating approxi-
mately 1000 molecules of thrombin) [5,6], and that
activated monocytes/macrophages participate in throm-
bosis, inflammation and atherosclerotic complications, we
compared the effects of the direct FXa inhibitor rivaroxa-
ban and the indirect imhibitor fondaparinux on both co-
agulation activation and chemokine secretion. Rivaroxaban
is a small chemical molecule and a specific inhibitor of fac-
tor Xa. In contrast, fondaparinux is a synthetic molecule
composed of five saccharides. It binds to antithrombin and
activates antithrombin. Once antithrombin forms a com-
plex with fondaparinux, it selectively neutralizes the activ-
ity of factor Xa. Both monocytes isolated from healthy
volunteers and human THP-1 macrophages were included
in this study.
Results
Increase in TF expressed on stimulated monocyte surface
In unstimulated cells, the TF expression was very low with
the mean of fluorescence close to the control without la-
beled specific anti-TF antibodies as shown in Figure 1A.
An important increase in TF expression was observed
in LPS-activated monocytes (Figure 1B). The TF expres-
sion level in the LPS-activated monocytes was not inter-
fered by the addition in culture media of rivaroxaban or
fondaparinux.
Effect of rivaroxaban and fondaparinux on the
endogenous procoagulant activity on monocytes and
macrophages surface in plasma
As shown in Figure 2, the addition of monocytes or
THP-1 to normal plasma triggered coagulation as mea-
sured with the recalcification clotting time. The addition
of the monocytes or THP-1 cells previously activated by
LPS, the recalcification time was shortened approxi-
mately to 50 seconds in comparison to the addition of
non-activated cells (approximately 125 seconds). This re-
sult was consistent with an increase in TF expression
level on activated cells.
Then we tested two anti-FXa drugs on the same test.
We observed that rivaroxaban inhibited the cell associated
procoagulant activity and prolonged clotting in both nor-
mal monocytes and THP-1 cells with or without LPS acti-
vation (Figure 2A,B,C,D). We converted clotting time to
human thromboplastin concentration (Figure 2E) and cal-
culated percent inhibition of procoagulant activity by the
two drugs. The results showed a clear difference between
Figure 1 Flow cytometry analysis of TF expression on non-activated monocytes and LPS-activated monocytes. The monocytes either
unstimulated (A) or LPS-stimulated (B) were incubated in presence of buffer (control) or fondaparinux (1.5 μg/ml) or rivaroxaban (0.35 g/ml) for
24 hours. Then the cells were washed and incubated with anti-TF antibodies and analyzed in the flow cytometry. The arrows showed increased
TF expression in the LPS-activated monocytes. The means of fluorescence intensity (MFI) of each sample minus MFI obtained from the controls
were shown.
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concentration-dependently to 12% of the procoagulant ac-
tivity on LPS-activated monocytes and THP-1, whereas
fondaparinux did not modify the procoagulant activity in
the same test.
Rivaroxaban and fondaparinux blocked thrombin
generation induced by THP-1 cells
We further used thrombin substrate SQ 150 to evalu-
ate thrombin generation after mixing the cells with
defibrinogen plasma and CaCl2. As shown in Figure 3A,
thrombin generation induced by the addition of LPS-stimulated THP-1 to plasma in the presence of cal-
cium, is partially blocked in the presence of fondapari-
nux, while it is almost completely blocked in the
presence of rivaroxaban.
To exclude other influences such as the degradation of
antithrombin III by secreted proteases from THP-1 cells,
antithrombin levels were controlled using a STA Stachrom
AT III kit. The addition of 0.35 μg/ml rivaroxaban or
1.5 μg/ml fondaparinux to activated or non-activated
THP1 in defibrinated plasma did not modify the level of
antithrombin III, excluding the suspected degradation of
AT III protein in the test system (Figure 3B).
Figure 2 Effect of rivaroxaban and fondaparinux on the cells triggering the plasma recalcification clotting time. Non-activated or
activated monocytes (A and B) and HP-1 cells (C and D) were used in the experiments. The cells were mixed with defibrinated plasma for
30 min and washed. Then CaCl2 and the cells were mixed with normal plasma and clotting time was recorded. The test was done in 5
independent experiments. E: Human thromboplastin was used to establish a linear curve in the same conditions without cells. *p < 0.05.
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and fondaparinux
We explored the cytokine release by THP-1 cells during
the generation of thrombin in defibrinated plasma and the
inhibitory effect of the two drugs on cytokine secretion.
The results showed that the activation of THP-1 cells by
LPS induced a significant increase in IL-8, a moderate in-
crease in Il-10, TNFα and Gro, and a slight increase in
MIP-1α, Rantes, EGF and MCP-1 (Figure 4A,B).Table 1 Inhibition of procoagulant activity with clotting time
Rivaroxaban (μg/ml)
0.15 0.25
Activated monocytes 30 ± 3* 16 ± 4*
Activated THP-1 42 ± 2* 24 ± 3*
Percent inhibition by two drugs of procoagulant activity was measured with clottin
independent experiments. 100% was the prothrombinase generated by thromboplaBoth rivaroxaban and fondaparinux modified these
changes in chemokine release. However, there are differ-
ences between the action of rivaroxaban and fondapari-
nux. Among these cytokines, we evaluated IL-8 and TNFα
by ELISA and the results showed these differences. Fon-
daparinux was responsible for a decrease in IL-8 secre-
tion by LPS activated THP-1 (43% by cytokine array and
36% by ELISA), whereas rivaroxaban had no effect on
IL-8 secretion (94% by cytokine array and 84% byFondaparinux (μg/ml)
0.35 0.5 1.0 1.5
12 ± 2* 105 ± 4 100 ± 6 105 ± 4
15 ± 1* 103 ± 7 102 ± 7 105 ± 8
g time assay compared to controls without drugs (100%). Mean ± SEM from 5
stin diluted 1/500 added to normal plasma. *p<0.05.
Figure 3 Thrombin generation and AT III activity. (A) Thrombin generation in platelet-poor plasma induced by the addition of LPS-activited
THP-1. Time–dependent thrombin generation was evaluated using a synthetic substrate SQ 150. Activated THP-1 cells were washed and added to
240 μl of defibrinated plasma and CaCl2. Fondaprinux at 1.5 μg/ml or 0.35 μg/ml rivaroxaban were added into the test in order to evaluate their inhibitory
effect. Optical density was measured. Significant differences were found among the three samples after 5 min reaction. (B) Antithrombin III activity in the
absence or presence of rivaroxaban and fondaparinux in platelet-poor plasma (PPP) mixed with non-activated or PLS-activated THP-1 cells. The results are
expressed as the percentage of AT activity in PPP. No statistical difference was found.
Laurent et al. Experimental Hematology & Oncology 2014, 3:30 Page 5 of 12
http://www.ehoonline.org/content/3/1/30ELISA) (Figure 5A). Fondaparinux also induced a slight
decrease in MCP-1, MIP, Rantes and TNFα secretion
whereas rivaroxaban had no effect on this cytokine se-
cretion. The action on TNFα secretion was also con-
firmed by ELISA (Figure 5B).
In addition, leptin and angiogenin secretion were mod-
erately reduced by both rivaroxaban and fondaparinux (re-
duction < 30%). Rivaroxaban induced a strong increase in
the anti-inflammatory cytokine IL-10 (198% of the secre-
tion of activated THP-1 cells).
Discussion
The results of flow cytometry showed that TF expression
level on monocytes was not directly modified by the pres-
ence of rivaroxaban or fondaparinux. Then we evaluatedenzymatic activity of FXa. In our study, the incubation
with defibrinated plasma provides plasma coagulation
factors to generate prothombinase activity on activated
monocytes or THP-1 cell surface. The defibrination was
carried out by reptilase and the procedure used in such
way does not alter coagulation factors involved in
thrombin generation and could avoid cell entrapment
into fibrin network and cytokine adsorption into fibrin
clot [35]. The results showed that LPS-activation upreg-
ulated TF expression in monocytes as well as their cell
membrane-associated procoagulant activity. The test of
prothrombinase activity bound to activated monocytes/
macrophages using thrombin substrate SQ 150 demon-
strated that the control LPS-activated THP-1 cells incu-
bated with platelet-poor plasma induce a time dependent
Figure 4 (See legend on next page.)
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Figure 4 Modulation of the cytokine secretion in THP-1 cells in response to fondaparinux and rivaroxaban. A: Cytokine Array. B: Data of
the cytokine assay. Non-activated and LPS-activated THP-1 cells were incubated in defibrinated plasma with PBS (control), 0.15 μg/ml fondaparinux or
0.35 μg/ml rivaroxaban. After 24 h, supernatants were assayed for cytokine production. All spots are in duplicate. a1, a2, and d12: positive controls. a3,
a4 and d11: negative controls. C: the quantification by Image J of cytokines secretion by LPS-activated THP-1 cells. Two independent experiments
were performed.
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blocked by rivaroxaban, whereas it was only partially
inhibited by fondaparinux. The experiments with recalcifi-
cation clotting time showed the same results that rivaroxa-
ban significantly prolonged the clotting time showing its
high efficiency in blocking the procoagulant activity of ac-
tivated monocytes and THP-1 macrophages. In contrast,
fondaparinux failed to significantly prolong the clotting
time showing a much lower efficiency in blocking cell-
associated procoagulant activity. The difference between
fondaparinux and rivaroxaban effects on the inhibition ofFigure 5 ELISA quantification of IL-8 and TNFα in THP-1 cells. Non-act
plasma in the presence of 0.35 μg/ml rivaroxaban or 1.5 μg/ml fondaparinu
data present is means ± SEM of 3 independent experiments. A: ELISA for IL
between non-activated cells versus control plasma; between non-activated
fondaparinux versus LPS-activated cells alone. B: ELISA for TNFα. Statistic sig
cells versus the control plasma; between activated cells treated by fondapacell-associated procoagulant activity could be explained
by different accessibility of these two drugs to FXa that
binds to cell membranes. As a small chemical molecule
rivaroxaban can easily get in contact with membrane-
bound FXa and inhibit its activity, whereas the complex
fondaparinux-AT with a heavy size is hard to get in con-
tact with cell-associated factor Xa due to a problem of
steric-hindrance. Our results are in agreement with the
results of Kakar et al., showing that by inhibiting both
free and bound factor Xa complexes, rivaroxaban pro-
longs activated partial thromboplastin time (aPTT) andivated or LPS-activated THP-1 cells were incubated in defibrinated
x. After 24 hours, IL-8 in the supernatants was measured by ELISA. The
-8. Statistic significance (p < 0.05) was found for the differences
versus LPS-activated cells; and between the activated cells treated by
nificance (p < 0.05) was found for the differences between activated
rinux versus LPS-activated cells alone.
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manner without antithrombin [36]. This differs from in-
direct FXa inhibitors, which only marginally prolonged
aPTT and PT. The possible degradation of antithrombin
by THP-1-releases proteases was excluded by AT III
assay in agreement with Wiesel et al. [37]. The higher
efficiency of rivaroxaban demonstrated in our study is
interesting because clinical studies also reported the re-
duction of thrombotic events in the rivaroxaban treated
patients group for hip and knee replacement in com-
parison to the enoxaparin-treated groups [38-41].
We evaluated the cytokine release in these cells since co-
agulation activation is known to stimulate the release of
pro-inflammatory cytokines [42-44]. Coagulation proteases
including FVIIa, FXa and thrombin bind and activate PARs
which are present on endothelial and mononuclear cells,
platelets, fibroblasts, and smooth muscle cells. We found
that activation of THP-1 cells by LPS induced an important
increase in IL-8, a moderate increase in Il-10, TNF and
Gro, and a slight increase in MIP-1α, Rantes, EGF and
MCP-1. Most of these cytokines are involved in angiogen-
esis. IL-8 regulats angiogenesis by enhancing endothelial
cell survival, proliferation, and matrix metalloproteinase
(MMPs) production [45]. TNFα is also a potent inducer of
angiogenesis [46]. The upregulation of these cytokines and
proangiogenic factors stimulate vascularization, monocyte
accumulation and the progression of atherosclerotic pla-
ques [47-49]. Importantly, vascularization in atheroscler-
otic plaque destabilizes the plaques and promotes its
rupture, which causes thrombosis and acute ischemic
events [50]. Histochemical examination of atherosclerotic
plaque from autopsy specimens demonstrated a strong
correlation between the severity of stenosis and plaque
microvascular density [51]. Rantes was reported to partici-
pate in plaque destabilization by inducing the secretion of
MMPs [52]. TNFα and Gro have been shown to be in-
volved in atherosclerotic plaqueprogression [53]. Groα was
among the top 10 most differentially expressed transcripts
in peripheral blood mononuclear cells from patients with
coronary artery disease in comparison with healthy con-
trols. The Groα expression in macrophages within symp-
tomatic carotid plaques was shown to enhance the release
of matrix metalloproteinases which causes plaque em-
brittlement and angiogenesis [54].
The effects of rivaroxaban and fondaparinux on the
cytokine release in activated macrophages are different.
Rivaroxaban, only induced a strong increase in the anti-
inflammatory cytokine IL-10 (198% of the secretion of
activated THP-1 cells). This increase could be involved
in the protection against atherosclerosis as suggested
[55]. The effect of fondaparinux was fairly different. Fon-
daparinux had no effect on Il-10 production. However, it
induced a clear decrease in IL-8 and to a less extent in
Rantes and TNFα. These changes could be beneficial inclinic for reducing atherosclerotic lesions because IL-8
plays an important role in initiation and maintenance of
the inflammatory microenvironment in atherosclerotic
plaques [56]. Moreover, a slight inhibition of angiogenin
transcription was observed when the cells had been
treated by fondaparinux or rivaroxaban.
Conclusion
Improving the efficiency of antithrombotic drugs is benefi-
cial not only for cardiovascular diseases, but also for ma-
lignant diseases. Our data demonstrate that rivaroxaban,
but not fondaparinux, inhibits efficiently the activation of
thrombin by cell-associated procoagulant activity relevant
to TF-FXa complex. This difference is most likely due to
the steric hindrance that prevents the contact of the com-
plex of fondaparinux-antithrombin with cell-associated
FXa. This mechanistic difference argues for a higher effi-
cacy of rivaroxaban as an antithrombotic drug in clinic.
Materials and methods
Plasma collection and inhibitor concentrations
Blood samples were collected from healthy volunteers in
trisodium citrate (0.105 M) at ratio of 9:1 (volume/volume)
and then centrifuged twice for 10 min (3000 g). Then
plasmas were collected. Defibrination was performed as
described by Dupuy et al. and Paysant et al. [57,58]. Briefly,
3 ml of normal plasma was incubated with 100 μl reptilase
(Stago, Asnières France) for 2 hours at room temperature.
Then, the fibrin clot was agglomerated on a glass stick to
obtain defibrinated plasma.
Rivaroxaban and fondaparinux were added to plasma
at concentrations based on the Cmax observed in pa-
tients plasma treated by anti-Xa agent: i.e. 0.15, 0.25 and
0.35 μg/ml for rivaroxaban and 0.5, 1.0 and 1.5 μg/ml
for fondaparinux.
Macrophage culture and monocyte isolation
THP-1 macrophages (Human acute monocytic leukemia
cell line) cells (ATCC) were cultured in RPMI 1640 cul-
ture medium containing 100 UI/ml penicillin (Eurobio),
100 μg/ml streptomycin (Eurobio), 2 mM L-glutamine
(Eurobio) and 10% heat inactivated fetal calf serum
(FCS, Eurobio). All cells were incubated in a humidified
incubator at 95% air, 5% carbon dioxide, at 37°C and used
within 20 passages.
Human mononuclear cells were isolated on a Ficoll
gradient as previously described [59]. Briefly, blood
from healthy volunteers was collected into polypropyl-
ene sterile tubes (Costar, Cambridge, MA) containing 1/5
(volume/volume) ACD (38 mM citric acid, 74 mM citrate,
136 mM glucose). After centrifugation (100 g, 10 min at
room temperature), platelet-rich plasma was removed to
minimize platelet contamination. Platelet-depleted blood
was placed into 50 ml Leucosep tubes (Costar) that
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160 g for 10 min at room temperature, mononuclear cells
were collected and washed three times in PBS (Eurobio).
Cells were incubated for 1 hour at 37°C in 5% CO2, 95%
water-saturated air mixture in 4 ml of AIM-V® medium
(Gibco). Non-adherent cells (lymphocytes are the major
type) were removed by two washes with PBS. Adherent
cells (approximately 85-90% are monocytes) were then
washed twice with PBS, detached with Accutase® cell de-
tachment solution (eBiosciences), washed and adjusted at
1 × 106/ml in PBS. Cells were counted by a Coulter
counter.
Monocyte and macrophage activation by
lipopolysaccharide (LPS)
Ten μg of LPS (Sigma) were added to 1 ml of monocytes
or THP-1 suspension (1 × 106 cells/ml) and then incu-
bated for 2 hours at 37°C with 5% CO2. Then cells were
washed.
Surface expression of TF on monocytes by immuno
fluorescence
Briefly, monocytes activated or not with LPS, were incu-
bated with defibrinated plasma in absence or presence of
rivaroxaban or fondaparinux and were resuspended by
pipetting. Then cells were washed twice in cold PBS. Ap-
proximately 1 × 106 cells were incubated for 15 minutes
at 4°C with 10 μl of FITC conjugated Mab anti-Human tis-
sue factor (4508CJ: 100 μg/ml Ig) obtained from American
Diagnostica. After two washes in PBS, the cell suspension
was analyzed in a flow cytometer. The monocyte popula-
tion was identified by gating the CD14 positive cells. A total
of 104 monocytes were analyzed. Results are expressed as a
mean of fluorescence intensity (MFI). For each sample the
background MFI produced by an isotype control antibody
(eBioscience), was subtracted from the MFI value generated
by the specific antibody.
Prothrombinase activity of monocytes and macrophages
treated or not by LPS
LPS-activated or non-activated monocytes or THP-1
were incubated with defibrinated plasma with either riv-
aroxaban or fondaparinux or saline (as control). Defi-
brinated plasma provides plasma coagulation factors to
generate prothombinase activity on LPS-activated mono-
cytes or THP-1 cell surface. Prothrombinase activity as-
sociated cells was evaluated by a 2 stage technique: 1)
prothrombinase complex assembly on cell surface was
performed by incubating 0.1 ml of a suspension of 1 × 106
monocytes or THP-1 for 30 min at 37°C, treated or not
with LPS, with 0.1 ml defibrinated plasma as a source of
plasma coagulation factors. Defibrinated plasma was used
in absence of anti-Xa agents (control) or in presence of
rivaroxaban (used at the 3 indicated concentrations) orfondaparinux (used at the 3 indicated concentrations). De-
fibrination was required to avoid monocyte/macrophage
sequestration in the fibrin clot and cytokine adsorption
into fibrin clot. The defibrination was carried out by repti-
lase under conditions described by Hemker et al. [35].
This method does not alter coagulation factors involved in
thrombin generation. Then cells were isolated by centrifu-
gation, washed and suspended into 0.1 ml PBS. 2) Cells as-
sociated prothrombinase activity was evaluated by adding
to a 0.1 ml cell suspension, 0.1 ml of plasma and 0.1 ml of
CaCl2 0.025 M. Results are expressed as a percentage of
procoagulant activity. The prothrombinase generated by
thromboplastin diluted 1/500 added to normal plasma
was considered 100%.
Thrombin generation evaluated on synthetic substrate by
incubation of plasma and CaCl2 with LPS activated
monocytes or THP-1
The 5 assays were carried out according to a slightly
modified technique of Peyrou et al. [60]. Briefly, 60 μl of
cells (1 × 106 cells/ml) and 160 μl of CaCl2 0.025 M were
added to 240 μl of defibrinated platelet-poor plasma con-
taining either 0.35 μg/ml of rivaroxaban or 1.5 μg/ml of
fondaparinux or a corresponding solvent (control). Then,
75 μl of each sample were obtained every 2 minutes for
10 min and transferred into a pre-warmed (37°C) dispos-
able tube containing 300 μl of 6 mM SQ 150 (Thrombin
substrate, Stago®) in Tris buffer pH 8.4. After 3 minutes,
the reaction was stopped by adding 15 μl of PPACK
1 mM. The supernatants optical density was evaluated at
405 nm with a Multiskan Ascent microplate reader from
Labsystems (Brumath®, France). The lag time, the maximal
thrombin concentration, and the time to maximal throm-
bin concentration were measured.
In order to evaluate all thrombin generated, without
taking into account thrombin bound to fibrin clot, the
experiments were performed using fibrinogen-depleted
plasma.
Determination of antithrombin (AT) in the supernatants
of activated THP-1 incubated with defibrinated plasma
AT was determined using STA Stachrom AT III kit
(Stago®). This test was carried out in order to investigate if
proteases released by activated THP-1 could degrade AT,
leading to a loss of its antithrombin activity.
Measurement by cytokine array of inflammatory
cytokines secreted by THP-1
Cytokine secretion was evaluated in a 24 well tissue cul-
ture plate Primaria Falcon (Becton Dickison): 300 μl of a
suspension of 1 × 106/ml THP1, either non activated or
activated by lipopolysaccharide (LPS) (under conditions
indicated above) were incubated in 300 μl defibrinated
plasma in order to provide plasma coagulation factors in
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oxaban at 1.5 μg/ml and 0.35 μg/ml respectively. Incuba-
tion was done for 24 hours at 37°C, 5% CO2. Then
media were collected and centrifuged at 1000 g for
10 minutes to discard cells.
Human Cytokine Antibody Array III kit (RayBiotech)
was used. Forty-two different cytokines were evaluated: Epi-
thelial Neutrophil-Activating peptide-78 (ENA-78), Gran-
ulocyte Colony-Stimulating Factor (GCSF), Granulocyte-
Macrophage Colony Stimulating Factor (GM-CSF), Growth
related oncoprotein (Gro), Groα, I-309, IL-1α, IL-1β, IL-2,
IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 p40p70, IL-13,
IL-15, INFγ, Monocyte Chemotactic Protein-1 (MCP-1),
MCP-2, MCP-3, Macrophage Colony Stimulating Factor
(MCSF), Macrophage-Derived Chemokine (MDC), Mono-
kine induced by IFNγ (MIG), Macrophage Inflammatory
Protein-1α (MIP-1α), Regulated on Activation Normal T
cell Expressed and Secreted (RANTES), human Stem Cell
Factor (SCF), Stromal-Derived Factor-1 (SDF-1), Thymus
and Activation- Regulated Chemokine (TARC), Transform-
ing Growth Factor-β1 (TGF- β1), TNF-α, TNF-β, Epider-
mal Growth Factor (EGF), Insulin-like Growth Factor-I
(IGF-I), Angiogenin, Oncostatin M, Thrombopoietin, Vas-
cular Endothelial Growth Factor (VEGF), Platelet-Derived
Growth Factor-BB (PDGF BB) and Leptin. Gro detected
CXC Ligand 1 (CXCL1), CXCL2 and CXCL3; Groα de-
tected only CXCL1. VEGF detected VEGF-165 and
VEGF-121.
Briefly, 1 ml supernatant medium were incubated with
arrayed antibody membranes, which were then exposed
to specific biotin-antibody cocktail, following the manu-
facturer's instructions. Signals were detected using
labeled-streptavidin by exposure on X-ray films.
We then compared the spot intensity on the samples:
1) activated or non-activated THP-1 cultured alone (to
control basic cytokine secretion and cytokines provided
by defibrinated plasma); 2) activated or non-activated
THP-1 incubated with rivaroxaban at 0.35 μg/ml, 3) ac-
tivated or non-activated THP-1 treated with fondapari-
nux at 1.5 μg/ml.
The area density of the spots was evaluated using image
J (written in Java) which was downloaded from the
National Center for Biotechnology Information. Signals
were normalized against the positive controls of each
membrane. The relative amount of each cytokine present
in the cell culture medium is presented as the fold in-
crease of the spot intensity in comparison to the superna-
tants of cytokines in control cells.
Determination by ELISA of IL-8 and TNFα in the supernatants
of non activated and LPS activated THP-1
IL-8 secretion level was measured by ELISA (kit Human
CXCL8/IL-8 Quantikine® R&D Systems) in the superna-
tants of non-activated and activated THP-1 incubatedwith defibrinated plasma in conditions described above,
in absence or presence of rivaroxaban at 0.35 μg/ml and
1.5 μg/ml fondaparinux. TNFα concentration in the su-
pernatants was determined using Human TNFα ELISA
Ready Set Go (eBioscience®) according to the manufac-
turer’s instructions.
Statistical analysis
One-way ANOVA and Mann–Whitney U tests were used.
The data are usually presented as mean ± SEM. The data
of ELISA is presented as mean ± SD. A probability value
of ≤0.05 was regarded as statistically significant.
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